Product Surveillance, Postmarketing
"Product Surveillance, Postmarketing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.
| Descriptor ID |
D011358
|
| MeSH Number(s) |
E05.337.800
|
| Concept/Terms |
Product Surveillance, Postmarketing- Product Surveillance, Postmarketing
- Product Surveillance, Post-Marketing
- Post-Marketing Product Surveillance
- Post-Marketing Product Surveillances
- Product Surveillance, Post Marketing
- Product Surveillances, Post-Marketing
- Surveillance, Post-Marketing Product
- Surveillances, Post-Marketing Product
- Evaluation Studies, Postmarketing
- Evaluation Study, Postmarketing
- Postmarketing Evaluation Studies
- Postmarketing Evaluation Study
- Studies, Postmarketing Evaluation
- Study, Postmarketing Evaluation
- Postmarketing Product Surveillance
- Postmarketing Product Surveillances
- Product Surveillances, Postmarketing
- Surveillance, Postmarketing Product
- Surveillances, Postmarketing Product
Drug Surveillance, Postmarketing- Drug Surveillance, Postmarketing
- Drug Surveillances, Postmarketing
- Postmarketing Drug Surveillance
- Postmarketing Drug Surveillances
- Surveillance, Postmarketing Drug
- Surveillances, Postmarketing Drug
|
Below are MeSH descriptors whose meaning is more general than "Product Surveillance, Postmarketing".
Below are MeSH descriptors whose meaning is more specific than "Product Surveillance, Postmarketing".
This graph shows the total number of publications written about "Product Surveillance, Postmarketing" by people in this website by year, and whether "Product Surveillance, Postmarketing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Product Surveillance, Postmarketing" by people in Profiles.
-
Active Surveillance of the Safety of Medications Used During Pregnancy. Am J Epidemiol. 2021 06 01; 190(6):1159-1168.
-
Exposure to Infliximab During Pregnancy: Post-Marketing Experience. Drug Saf. 2020 02; 43(2):147-161.
-
Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. Int J Cardiol. 2019 05 15; 283:67-72.
-
1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration. JACC Cardiovasc Interv. 2018 10 08; 11(19):1969-1978.
-
Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses. Am J Epidemiol. 2018 08 01; 187(8):1799-1807.
-
Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 02; 77(2):228-233.
-
"First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs. Am J Epidemiol. 2014 Sep 15; 180(6):636-44.
-
A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. Pharmacoepidemiol Drug Saf. 2014 Jun; 23(6):619-27.
-
Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal. Expert Opin Pharmacother. 2012 Dec; 13(17):2555-63.
-
The role of the U.S. Food and Drug Administration in device evaluation and monitoring. Gastrointest Endosc. 2010 Jul; 72(1):5-10.